Document Detail


Aripiprazole in the treatment of challenging behaviour in adults with autism spectrum disorder.
MedLine Citation:
PMID:  22535309     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Autism spectrum disorders (ASD) are associated with repetitive behaviours and often also with hyperactivity, aggression, self-injurious behaviour, irritability and lability of mood. There is emerging evidence that aripiprazole, an antipsychotic with partial agonist dopaminergic effect, may be effective in the treatment of these challenging behaviours. Nevertheless, there is little evidence for their efficacy in adults with ASD.
OBJECTIVES: The aim of this article is to present preliminary data on the use of aripiprazole in the treatment of challenging behaviour in the setting of ASD.
METHODS: We present a consecutive series of five inpatients of normal intelligence with challenging behaviour associated with ASD, diagnosed according to ICD-10 criteria, which was resistant to treatment with other medical and behavioural interventions and which was treated with aripiprazole.
RESULTS: Four out of five patients were classified as "much improved" or "very much improved" according to the Clinical Global Impression-Improvement scale. Aripiprazole caused akathisia, at a dose of 30 mg in the one patient who was not classified as a responder but was otherwise well tolerated.
CONCLUSIONS: This is the first case series of adults with ASD presenting with challenging behaviour who have been treated with aripiprazole. While the results are promising, controlled trials are required to confirm the findings.
Authors:
Iain Jordan; Dene Robertson; Marco Catani; Michael Craig; Declan Murphy
Related Documents :
22893809 - Marital quality and relationship satisfaction in war veterans and their wives in bosnia...
22511399 - Effects of an uncertainty management intervention on uncertainty, anxiety, depression, ...
16279279 - The society for clinical trials supports united states legislation mandating trials reg...
1012899 - Experience and latency to achieve stereopsis.
22686549 - Does problem-solving training for family caregivers benefit their care recipients with ...
17373219 - Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
21531089 - Motivational interviewing to reduce substance-related consequences: effects for incarce...
23633849 - Prevention of post-partum hemorrhage by rectal misoprostol: a randomized clinical trial.
22893809 - Marital quality and relationship satisfaction in war veterans and their wives in bosnia...
Publication Detail:
Type:  Journal Article     Date:  2012-04-26
Journal Detail:
Title:  Psychopharmacology     Volume:  223     ISSN:  1432-2072     ISO Abbreviation:  Psychopharmacology (Berl.)     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-09-11     Completed Date:  2013-02-04     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  7608025     Medline TA:  Psychopharmacology (Berl)     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  357-60     Citation Subset:  IM    
Affiliation:
Department of Forensic and Neurodevelopmental Science, Institute of Psychiatry, 16 De Crespigny Park, London, SE5 8AF, UK. iain_jordan@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antipsychotic Agents / administration & dosage,  therapeutic use*
Behavior / drug effects*
Child
Child Development Disorders, Pervasive / drug therapy*,  psychology*
Female
Humans
Male
Piperazines / administration & dosage,  therapeutic use*
Quinolones / administration & dosage,  therapeutic use*
Treatment Outcome
Young Adult
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 0/Piperazines; 0/Quinolones; 82VFR53I78/aripiprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cocaine self-administration behaviors in Clock?19 mice.
Next Document:  Intermittent Explosive Disorder as a Disorder of Impulsive Aggression for DSM-5.